SlideShare a Scribd company logo
1 of 32
Comparison of Dopamine and Norepinephrinein the Treatment of Shock ALLAN PEPE VASQUEZ TEJADA  Medico Residente de Cirugía. HVLE
El control de la presión tiene dos regulaciones  Regulación rápida  Barorreceptores de alta presión y de baja presión Regulacion de largo plazo
El centro de la presión arterial se encuentra en el bulbo raquídeo rostral ventrolateral y se conecta con la columna intermedio lateral de la medula espinal y con el vago. La noradrenalina, la adrenalina y dopamina son vasopresoresendogenos que tiene diferente forma de acción
SHOCK
DOPAMINA La dopamina (3,4-dihidroxifeniletilamina) produce vasodilatación renal Causan estimulación del miocardio Estimulan la frecuencia cardíaca y la vasoconstricción periférica
Actualmente la dopamina no está recomendada a dosis bajas Estas acciones determinan un incremento en el consumo de oxígeno miocárdico debido a un aumento en la frecuencia cardíaca y en la vasoconstricción coronaria En pacientes con miocardio agudamente isquémico, la dopamina puede inducir arritmias y precipitar angina.
NORADRENALINA Es un agonista potente de los receptores –adrenérgicos El gasto cardíaco persiste sin cambios o está disminuido Aumenta en grado importante el flujo coronario Recomendada la infusión de norepinefrina en choque donde no se logra una estabilidad con la dopamina
"La dopamina es el fármaco de elección para el shock" (Vincent 1999).“ se indica para revertir la hipotensión hemodinámicamente significativa debida a infarto miocárdico, traumatismo, sepsis, insuficiencia cardíaca manifiesta, insuficiencia renal, insuficiencia cardíaca congestiva crónica..." (Levy 1992).  "La norepinefrina parece ser sumamente útil en el tratamiento del shock causado por disminución inapropiada en la resistencia vascular periférica como el shock séptico y el neurogénico"
"La epinefrina se indica principalmente para los estados de gasto cardíaco bajo" (Sladen 1999) y se recomienda como "el tratamiento de primera línea en pacientes con shock anafiláctico" (Breithaupt 2000; Vincent 1999).  "La dobutamina es muy eficaz en pacientes con miocardiopatía e insuficiencia cardíaca congestiva" (Sladen 1999).
Tres estudios compararon norepinefrina con dopamina (Marik 1994; Martin 1993; Ruokonen 1993): 16 pacientes de 31 murieron en el grupo de norepinefrina en comparación con 19 de 31 en el grupo de dopamina (RR 0,88; 0,57 a 1,36) (ver comparación 02, el resultado 01).
ESTUDIO
Theadministration of fluids, which is the first-line therapeutic strategy, is often insufficient to stabilize the patient’s condition, and adrenergic agents are frequently required to correct hypotension.
Dopamineand norepinephrine influence alpha-adrenergic and beta-adrenergic receptors, but to different degrees  Dopamine and norepinephrine may have different effects on the kidney, the splanchnic region, and the pituitary axis, but the clinical implications of these differences are still uncertain.
Multicentertrial betweenDecember19, 2003, and October 6, 2007, in eight centers in Belgium, Austria, and Spain. 18 years of age or older
Thepatientwasconsideredto be in shock if the PAM was less than 70 mm Hg or the PAS was less than 100 mm Hg o there was an elevation in the central venous pressure to >12 mm Hg and if there were signs of tissue hypoperfusion
Patientswere excluded if had already received a vasopressoragentfor more than 4 hours during the current episode of shock had a serious arrhythmia had been declaredbrain-dead.
The study period lasted a maximum of 28 days The primary end point of the trial was the rate of deathat 28 days
A total of 1679 patients were enrolled — 858 in the dopamine group and 821 in the norepinephinegroup. Therewere no significantdifferences between the two groups withregardto most of the baseline characteristics
The type of shock that was seen most frequently was septic shock (in 1044 patients ), followed by cardiogenic shock (in 280 patients) and hypovolemicshock (in 263 patients).  Hydrocortisone was administered in 344 patients who received dopamine (40.1%) and in 326 patients who received norepinephrine(39.7%)
There were no major between-group differences in the total amounts of fluid given, although patients in the dopamine group received more fluids on day 1 Urine output was significantly higher during the first 24 hours in the dopamine group than among those in the norepinephrine group, but this difference eventually disappeared, so that the fluid balance was quite similar between the twogroups.
Therewere no significantdifferences in the causes of death between the two groups, although death from refractory shock occurred more frequently in the group of patients treated with dopamine than in the group treated with norepinephrine (P = 0.05)
More patients had an arrhythmia, especially atrial fibrillation, in the dopamine group than in the norepinephrinegroup The rate of death at 28 days was significantly higher among patients with cardiogenic shock who were treated with dopamine than among those with cardiogenic shock who were treated with norepinephrine (P = 0.03)
The rate of death at 28 days was significantly higher among patients with cardiogenic shock who were treated with dopamine than among those with cardiogenic shock who were treated with norepinephrine (P = 0.03)
CONCLUSIONES
The rate of death did not differ significantly between the group of patients treated with dopamine and the group treated with norepinephrine Dopamine was associated with more arrhythmic events than was norepinephrine Dopaminewasassociatedwith a significant increase in the rate of death in the predefined subgroup of patients with cardiogenicshock.
GRACIAS

More Related Content

What's hot

management of acute Heart failure
management of acute Heart failure management of acute Heart failure
management of acute Heart failure Basem Enany
 
Angina Management with Metabolic Agents
Angina Management with Metabolic AgentsAngina Management with Metabolic Agents
Angina Management with Metabolic AgentsPERKI Pekanbaru
 
refractory angina new hope
refractory angina new hoperefractory angina new hope
refractory angina new hopeAhmed Taha
 
Ahmad aa proarrhythmia
Ahmad aa   proarrhythmiaAhmad aa   proarrhythmia
Ahmad aa proarrhythmiaMostafa Sobhy
 
New pharmocological agents in the management of angina nicorandil
New pharmocological agents in the management of angina nicorandilNew pharmocological agents in the management of angina nicorandil
New pharmocological agents in the management of angina nicorandilJerin Kuruvilla
 
acute heart failure:therapeutic update
acute heart failure:therapeutic updateacute heart failure:therapeutic update
acute heart failure:therapeutic updatemagdy elmasry
 
Péptidos natriuréticos, nuestra protección endógena frente a la IC
Péptidos natriuréticos, nuestra protección endógena frente a la ICPéptidos natriuréticos, nuestra protección endógena frente a la IC
Péptidos natriuréticos, nuestra protección endógena frente a la ICSociedad Española de Cardiología
 
Nuove Prospective nel trattamento dello scompenso acuto
Nuove Prospective nel trattamento dello scompenso acutoNuove Prospective nel trattamento dello scompenso acuto
Nuove Prospective nel trattamento dello scompenso acutodrucsamal
 
Acute Decompensated Heart Failure
Acute Decompensated Heart FailureAcute Decompensated Heart Failure
Acute Decompensated Heart Failuredrucsamal
 
Acls guidelines for brady cardia and tachycardia
Acls guidelines for brady cardia and tachycardiaAcls guidelines for brady cardia and tachycardia
Acls guidelines for brady cardia and tachycardiamegha soni
 
Summary of PROVE-HF and GUIDE-IT studies by Dr. Vaibhav Yawalkar MD, DM Cardi...
Summary of PROVE-HF and GUIDE-IT studies by Dr. Vaibhav Yawalkar MD, DM Cardi...Summary of PROVE-HF and GUIDE-IT studies by Dr. Vaibhav Yawalkar MD, DM Cardi...
Summary of PROVE-HF and GUIDE-IT studies by Dr. Vaibhav Yawalkar MD, DM Cardi...vaibhavyawalkar
 
Fusaro - Renal Denervation, current evidence and new technical developments
Fusaro - Renal Denervation, current evidence and new technical developmentsFusaro - Renal Denervation, current evidence and new technical developments
Fusaro - Renal Denervation, current evidence and new technical developmentsSalutaria
 

What's hot (19)

management of acute Heart failure
management of acute Heart failure management of acute Heart failure
management of acute Heart failure
 
Angina Management with Metabolic Agents
Angina Management with Metabolic AgentsAngina Management with Metabolic Agents
Angina Management with Metabolic Agents
 
refractory angina new hope
refractory angina new hoperefractory angina new hope
refractory angina new hope
 
Ahmad aa proarrhythmia
Ahmad aa   proarrhythmiaAhmad aa   proarrhythmia
Ahmad aa proarrhythmia
 
New pharmocological agents in the management of angina nicorandil
New pharmocological agents in the management of angina nicorandilNew pharmocological agents in the management of angina nicorandil
New pharmocological agents in the management of angina nicorandil
 
acute decompensated heart failure
acute decompensated heart failureacute decompensated heart failure
acute decompensated heart failure
 
acute heart failure:therapeutic update
acute heart failure:therapeutic updateacute heart failure:therapeutic update
acute heart failure:therapeutic update
 
Péptidos natriuréticos, nuestra protección endógena frente a la IC
Péptidos natriuréticos, nuestra protección endógena frente a la ICPéptidos natriuréticos, nuestra protección endógena frente a la IC
Péptidos natriuréticos, nuestra protección endógena frente a la IC
 
Nuove Prospective nel trattamento dello scompenso acuto
Nuove Prospective nel trattamento dello scompenso acutoNuove Prospective nel trattamento dello scompenso acuto
Nuove Prospective nel trattamento dello scompenso acuto
 
Acute Decompensated Heart Failure
Acute Decompensated Heart FailureAcute Decompensated Heart Failure
Acute Decompensated Heart Failure
 
Acls guidelines for brady cardia and tachycardia
Acls guidelines for brady cardia and tachycardiaAcls guidelines for brady cardia and tachycardia
Acls guidelines for brady cardia and tachycardia
 
Antiarrhythmics
AntiarrhythmicsAntiarrhythmics
Antiarrhythmics
 
Acei
AceiAcei
Acei
 
Summary of PROVE-HF and GUIDE-IT studies by Dr. Vaibhav Yawalkar MD, DM Cardi...
Summary of PROVE-HF and GUIDE-IT studies by Dr. Vaibhav Yawalkar MD, DM Cardi...Summary of PROVE-HF and GUIDE-IT studies by Dr. Vaibhav Yawalkar MD, DM Cardi...
Summary of PROVE-HF and GUIDE-IT studies by Dr. Vaibhav Yawalkar MD, DM Cardi...
 
Innovations in the Diagnosis and Treatment of Chronic Heart Failure
Innovations in the Diagnosis and Treatment of Chronic Heart FailureInnovations in the Diagnosis and Treatment of Chronic Heart Failure
Innovations in the Diagnosis and Treatment of Chronic Heart Failure
 
Fusaro - Renal Denervation, current evidence and new technical developments
Fusaro - Renal Denervation, current evidence and new technical developmentsFusaro - Renal Denervation, current evidence and new technical developments
Fusaro - Renal Denervation, current evidence and new technical developments
 
Sasi hypertensive emergensies
Sasi hypertensive emergensiesSasi hypertensive emergensies
Sasi hypertensive emergensies
 
Randil
RandilRandil
Randil
 
Heart failure management - role of arni
Heart failure management - role of arniHeart failure management - role of arni
Heart failure management - role of arni
 

Similar to Alan dopamine and norepinephrine

Shock And Vasoactive Drugs
Shock And Vasoactive DrugsShock And Vasoactive Drugs
Shock And Vasoactive DrugsMuhammad Badawi
 
COMPARISON OF DOPAMINE AND NORADRENALINE IN SHOCK TREATMENT
COMPARISON OF DOPAMINE AND NORADRENALINE IN SHOCK TREATMENTCOMPARISON OF DOPAMINE AND NORADRENALINE IN SHOCK TREATMENT
COMPARISON OF DOPAMINE AND NORADRENALINE IN SHOCK TREATMENTSanthu Cheekoti
 
Haemodynamic drug infusions
Haemodynamic drug infusionsHaemodynamic drug infusions
Haemodynamic drug infusionswael ezzat
 
hypertensiveemergencies-160418043048.pdf
hypertensiveemergencies-160418043048.pdfhypertensiveemergencies-160418043048.pdf
hypertensiveemergencies-160418043048.pdfDrYaqoobBahar
 
Potential new therapies in heart failure
Potential new therapies in heart failurePotential new therapies in heart failure
Potential new therapies in heart failureAnirudhya J
 
MANAGEMENT OF ATRIAL FIBRILLATION.pptx
MANAGEMENT OF ATRIAL FIBRILLATION.pptxMANAGEMENT OF ATRIAL FIBRILLATION.pptx
MANAGEMENT OF ATRIAL FIBRILLATION.pptxJagtishViramuthu
 
Ryanodex,a new dantrolene formulation
Ryanodex,a new dantrolene formulation Ryanodex,a new dantrolene formulation
Ryanodex,a new dantrolene formulation Claudio Melloni
 
Hypertension and stroke
Hypertension and stroke Hypertension and stroke
Hypertension and stroke PS Deb
 
Rational choice of inotropes and vasopressors in intensive care unit
Rational choice of inotropes and vasopressors in intensive care unitRational choice of inotropes and vasopressors in intensive care unit
Rational choice of inotropes and vasopressors in intensive care unitSaneesh P J
 
Clozapine and its cardiac adverse effects
Clozapine and its cardiac adverse effectsClozapine and its cardiac adverse effects
Clozapine and its cardiac adverse effectsAdonis Sfera, MD
 
Treatement of Angina Pectoris
Treatement of Angina PectorisTreatement of Angina Pectoris
Treatement of Angina PectorisPrernaPandey37
 
Abcd emergency drugs
Abcd emergency drugsAbcd emergency drugs
Abcd emergency drugsOrdeen McLean
 
Guidelines for management of acute stroke
Guidelines for management of acute strokeGuidelines for management of acute stroke
Guidelines for management of acute strokesankalpgmc8
 
Nitrate as First Line Monotherapy for Pulmonary Oedema
 Nitrate as First Line Monotherapy for Pulmonary Oedema Nitrate as First Line Monotherapy for Pulmonary Oedema
Nitrate as First Line Monotherapy for Pulmonary Oedemaد. أنور الموسوي
 
Nitrate as First Line Monotherapy for Pulmonary Oedema
 Nitrate as First Line Monotherapy for Pulmonary Oedema Nitrate as First Line Monotherapy for Pulmonary Oedema
Nitrate as First Line Monotherapy for Pulmonary Oedemaد. أنور الموسوي
 
inotropic drugs and vassopressors drugs.pptx
inotropic drugs and vassopressors drugs.pptxinotropic drugs and vassopressors drugs.pptx
inotropic drugs and vassopressors drugs.pptxAhmed638947
 

Similar to Alan dopamine and norepinephrine (20)

Shock And Vasoactive Drugs
Shock And Vasoactive DrugsShock And Vasoactive Drugs
Shock And Vasoactive Drugs
 
COMPARISON OF DOPAMINE AND NORADRENALINE IN SHOCK TREATMENT
COMPARISON OF DOPAMINE AND NORADRENALINE IN SHOCK TREATMENTCOMPARISON OF DOPAMINE AND NORADRENALINE IN SHOCK TREATMENT
COMPARISON OF DOPAMINE AND NORADRENALINE IN SHOCK TREATMENT
 
Haemodynamic drug infusions
Haemodynamic drug infusionsHaemodynamic drug infusions
Haemodynamic drug infusions
 
Hypertensive emergencies
Hypertensive emergenciesHypertensive emergencies
Hypertensive emergencies
 
hypertensiveemergencies-160418043048.pdf
hypertensiveemergencies-160418043048.pdfhypertensiveemergencies-160418043048.pdf
hypertensiveemergencies-160418043048.pdf
 
Vasopressors in Sepsis
Vasopressors in SepsisVasopressors in Sepsis
Vasopressors in Sepsis
 
Potential new therapies in heart failure
Potential new therapies in heart failurePotential new therapies in heart failure
Potential new therapies in heart failure
 
MANAGEMENT OF ATRIAL FIBRILLATION.pptx
MANAGEMENT OF ATRIAL FIBRILLATION.pptxMANAGEMENT OF ATRIAL FIBRILLATION.pptx
MANAGEMENT OF ATRIAL FIBRILLATION.pptx
 
Ryanodex,a new dantrolene formulation
Ryanodex,a new dantrolene formulation Ryanodex,a new dantrolene formulation
Ryanodex,a new dantrolene formulation
 
Hypertension and stroke
Hypertension and stroke Hypertension and stroke
Hypertension and stroke
 
Rational choice of inotropes and vasopressors in intensive care unit
Rational choice of inotropes and vasopressors in intensive care unitRational choice of inotropes and vasopressors in intensive care unit
Rational choice of inotropes and vasopressors in intensive care unit
 
Epnone in ccf
Epnone in ccfEpnone in ccf
Epnone in ccf
 
Clozapine and its cardiac adverse effects
Clozapine and its cardiac adverse effectsClozapine and its cardiac adverse effects
Clozapine and its cardiac adverse effects
 
Treatement of Angina Pectoris
Treatement of Angina PectorisTreatement of Angina Pectoris
Treatement of Angina Pectoris
 
Abcd emergency drugs
Abcd emergency drugsAbcd emergency drugs
Abcd emergency drugs
 
Guidelines for management of acute stroke
Guidelines for management of acute strokeGuidelines for management of acute stroke
Guidelines for management of acute stroke
 
Nitrate as First Line Monotherapy for Pulmonary Oedema
 Nitrate as First Line Monotherapy for Pulmonary Oedema Nitrate as First Line Monotherapy for Pulmonary Oedema
Nitrate as First Line Monotherapy for Pulmonary Oedema
 
Nitrate as First Line Monotherapy for Pulmonary Oedema
 Nitrate as First Line Monotherapy for Pulmonary Oedema Nitrate as First Line Monotherapy for Pulmonary Oedema
Nitrate as First Line Monotherapy for Pulmonary Oedema
 
Consensus Trial
Consensus TrialConsensus Trial
Consensus Trial
 
inotropic drugs and vassopressors drugs.pptx
inotropic drugs and vassopressors drugs.pptxinotropic drugs and vassopressors drugs.pptx
inotropic drugs and vassopressors drugs.pptx
 

More from universidad san marcos

2010 guías para la resucitación lobitoferoz13
2010 guías para la resucitación lobitoferoz132010 guías para la resucitación lobitoferoz13
2010 guías para la resucitación lobitoferoz13universidad san marcos
 
Sedoanalgesia en uci 2010 lobitoferoz13
Sedoanalgesia en uci 2010 lobitoferoz13Sedoanalgesia en uci 2010 lobitoferoz13
Sedoanalgesia en uci 2010 lobitoferoz13universidad san marcos
 
Dopamine and norepinephrine lobitoferoz13
Dopamine and norepinephrine lobitoferoz13Dopamine and norepinephrine lobitoferoz13
Dopamine and norepinephrine lobitoferoz13universidad san marcos
 
Weaning from ventilatory support lobitoferoz13
Weaning from ventilatory support lobitoferoz13Weaning from ventilatory support lobitoferoz13
Weaning from ventilatory support lobitoferoz13universidad san marcos
 
Perfusión y oxigenación tisular gabina
Perfusión y oxigenación tisular gabinaPerfusión y oxigenación tisular gabina
Perfusión y oxigenación tisular gabinauniversidad san marcos
 
Drogas inotropicas lic. zayda tapia ojeda
Drogas inotropicas lic. zayda tapia ojedaDrogas inotropicas lic. zayda tapia ojeda
Drogas inotropicas lic. zayda tapia ojedauniversidad san marcos
 

More from universidad san marcos (20)

Cetoacidosis diabetica lobitoferoz13
Cetoacidosis diabetica lobitoferoz13Cetoacidosis diabetica lobitoferoz13
Cetoacidosis diabetica lobitoferoz13
 
2010 guías rcp lobitoferoz13
2010 guías rcp lobitoferoz132010 guías rcp lobitoferoz13
2010 guías rcp lobitoferoz13
 
2010 guías para la resucitación lobitoferoz13
2010 guías para la resucitación lobitoferoz132010 guías para la resucitación lobitoferoz13
2010 guías para la resucitación lobitoferoz13
 
Neuro enfer
Neuro  enferNeuro  enfer
Neuro enfer
 
Neuro enfer
Neuro  enferNeuro  enfer
Neuro enfer
 
Equidad gerencia
Equidad  gerenciaEquidad  gerencia
Equidad gerencia
 
Sedoanalgesia en uci 2010 lobitoferoz13
Sedoanalgesia en uci 2010 lobitoferoz13Sedoanalgesia en uci 2010 lobitoferoz13
Sedoanalgesia en uci 2010 lobitoferoz13
 
Cad 2010 lobitoferoz13
Cad 2010 lobitoferoz13Cad 2010 lobitoferoz13
Cad 2010 lobitoferoz13
 
Cad 2010 lobitoferoz13
Cad 2010 lobitoferoz13Cad 2010 lobitoferoz13
Cad 2010 lobitoferoz13
 
Dopamine and norepinephrine lobitoferoz13
Dopamine and norepinephrine lobitoferoz13Dopamine and norepinephrine lobitoferoz13
Dopamine and norepinephrine lobitoferoz13
 
Capnometria en tep lobitoferoz13
Capnometria en tep lobitoferoz13Capnometria en tep lobitoferoz13
Capnometria en tep lobitoferoz13
 
Weaning from ventilatory support lobitoferoz13
Weaning from ventilatory support lobitoferoz13Weaning from ventilatory support lobitoferoz13
Weaning from ventilatory support lobitoferoz13
 
Trali lobitoferoz13
Trali lobitoferoz13Trali lobitoferoz13
Trali lobitoferoz13
 
Capnometria en tep lobitoferoz13
Capnometria en tep lobitoferoz13Capnometria en tep lobitoferoz13
Capnometria en tep lobitoferoz13
 
Tec grave lobitoferoz13
Tec grave lobitoferoz13Tec grave lobitoferoz13
Tec grave lobitoferoz13
 
Perfusión y oxigenación tisular gabina
Perfusión y oxigenación tisular gabinaPerfusión y oxigenación tisular gabina
Perfusión y oxigenación tisular gabina
 
Falla renal uci lobitoferoz13
Falla renal uci lobitoferoz13Falla renal uci lobitoferoz13
Falla renal uci lobitoferoz13
 
Oxigenoterapia
OxigenoterapiaOxigenoterapia
Oxigenoterapia
 
Drogas inotropicas lic. zayda tapia ojeda
Drogas inotropicas lic. zayda tapia ojedaDrogas inotropicas lic. zayda tapia ojeda
Drogas inotropicas lic. zayda tapia ojeda
 
oxigenoterapia lic Mrgoth
oxigenoterapia lic Mrgothoxigenoterapia lic Mrgoth
oxigenoterapia lic Mrgoth
 

Recently uploaded

Crayon Activity Handout For the Crayon A
Crayon Activity Handout For the Crayon ACrayon Activity Handout For the Crayon A
Crayon Activity Handout For the Crayon AUnboundStockton
 
Final demo Grade 9 for demo Plan dessert.pptx
Final demo Grade 9 for demo Plan dessert.pptxFinal demo Grade 9 for demo Plan dessert.pptx
Final demo Grade 9 for demo Plan dessert.pptxAvyJaneVismanos
 
Earth Day Presentation wow hello nice great
Earth Day Presentation wow hello nice greatEarth Day Presentation wow hello nice great
Earth Day Presentation wow hello nice greatYousafMalik24
 
Capitol Tech U Doctoral Presentation - April 2024.pptx
Capitol Tech U Doctoral Presentation - April 2024.pptxCapitol Tech U Doctoral Presentation - April 2024.pptx
Capitol Tech U Doctoral Presentation - April 2024.pptxCapitolTechU
 
Introduction to AI in Higher Education_draft.pptx
Introduction to AI in Higher Education_draft.pptxIntroduction to AI in Higher Education_draft.pptx
Introduction to AI in Higher Education_draft.pptxpboyjonauth
 
Organic Name Reactions for the students and aspirants of Chemistry12th.pptx
Organic Name Reactions  for the students and aspirants of Chemistry12th.pptxOrganic Name Reactions  for the students and aspirants of Chemistry12th.pptx
Organic Name Reactions for the students and aspirants of Chemistry12th.pptxVS Mahajan Coaching Centre
 
Types of Journalistic Writing Grade 8.pptx
Types of Journalistic Writing Grade 8.pptxTypes of Journalistic Writing Grade 8.pptx
Types of Journalistic Writing Grade 8.pptxEyham Joco
 
KSHARA STURA .pptx---KSHARA KARMA THERAPY (CAUSTIC THERAPY)————IMP.OF KSHARA ...
KSHARA STURA .pptx---KSHARA KARMA THERAPY (CAUSTIC THERAPY)————IMP.OF KSHARA ...KSHARA STURA .pptx---KSHARA KARMA THERAPY (CAUSTIC THERAPY)————IMP.OF KSHARA ...
KSHARA STURA .pptx---KSHARA KARMA THERAPY (CAUSTIC THERAPY)————IMP.OF KSHARA ...M56BOOKSTORE PRODUCT/SERVICE
 
18-04-UA_REPORT_MEDIALITERAСY_INDEX-DM_23-1-final-eng.pdf
18-04-UA_REPORT_MEDIALITERAСY_INDEX-DM_23-1-final-eng.pdf18-04-UA_REPORT_MEDIALITERAСY_INDEX-DM_23-1-final-eng.pdf
18-04-UA_REPORT_MEDIALITERAСY_INDEX-DM_23-1-final-eng.pdfssuser54595a
 
Framing an Appropriate Research Question 6b9b26d93da94caf993c038d9efcdedb.pdf
Framing an Appropriate Research Question 6b9b26d93da94caf993c038d9efcdedb.pdfFraming an Appropriate Research Question 6b9b26d93da94caf993c038d9efcdedb.pdf
Framing an Appropriate Research Question 6b9b26d93da94caf993c038d9efcdedb.pdfUjwalaBharambe
 
Painted Grey Ware.pptx, PGW Culture of India
Painted Grey Ware.pptx, PGW Culture of IndiaPainted Grey Ware.pptx, PGW Culture of India
Painted Grey Ware.pptx, PGW Culture of IndiaVirag Sontakke
 
Meghan Sutherland In Media Res Media Component
Meghan Sutherland In Media Res Media ComponentMeghan Sutherland In Media Res Media Component
Meghan Sutherland In Media Res Media ComponentInMediaRes1
 
Roles & Responsibilities in Pharmacovigilance
Roles & Responsibilities in PharmacovigilanceRoles & Responsibilities in Pharmacovigilance
Roles & Responsibilities in PharmacovigilanceSamikshaHamane
 
History Class XII Ch. 3 Kinship, Caste and Class (1).pptx
History Class XII Ch. 3 Kinship, Caste and Class (1).pptxHistory Class XII Ch. 3 Kinship, Caste and Class (1).pptx
History Class XII Ch. 3 Kinship, Caste and Class (1).pptxsocialsciencegdgrohi
 
भारत-रोम व्यापार.pptx, Indo-Roman Trade,
भारत-रोम व्यापार.pptx, Indo-Roman Trade,भारत-रोम व्यापार.pptx, Indo-Roman Trade,
भारत-रोम व्यापार.pptx, Indo-Roman Trade,Virag Sontakke
 
Proudly South Africa powerpoint Thorisha.pptx
Proudly South Africa powerpoint Thorisha.pptxProudly South Africa powerpoint Thorisha.pptx
Proudly South Africa powerpoint Thorisha.pptxthorishapillay1
 
How to Configure Email Server in Odoo 17
How to Configure Email Server in Odoo 17How to Configure Email Server in Odoo 17
How to Configure Email Server in Odoo 17Celine George
 

Recently uploaded (20)

Crayon Activity Handout For the Crayon A
Crayon Activity Handout For the Crayon ACrayon Activity Handout For the Crayon A
Crayon Activity Handout For the Crayon A
 
Final demo Grade 9 for demo Plan dessert.pptx
Final demo Grade 9 for demo Plan dessert.pptxFinal demo Grade 9 for demo Plan dessert.pptx
Final demo Grade 9 for demo Plan dessert.pptx
 
Earth Day Presentation wow hello nice great
Earth Day Presentation wow hello nice greatEarth Day Presentation wow hello nice great
Earth Day Presentation wow hello nice great
 
Model Call Girl in Bikash Puri Delhi reach out to us at 🔝9953056974🔝
Model Call Girl in Bikash Puri  Delhi reach out to us at 🔝9953056974🔝Model Call Girl in Bikash Puri  Delhi reach out to us at 🔝9953056974🔝
Model Call Girl in Bikash Puri Delhi reach out to us at 🔝9953056974🔝
 
Capitol Tech U Doctoral Presentation - April 2024.pptx
Capitol Tech U Doctoral Presentation - April 2024.pptxCapitol Tech U Doctoral Presentation - April 2024.pptx
Capitol Tech U Doctoral Presentation - April 2024.pptx
 
Introduction to AI in Higher Education_draft.pptx
Introduction to AI in Higher Education_draft.pptxIntroduction to AI in Higher Education_draft.pptx
Introduction to AI in Higher Education_draft.pptx
 
Organic Name Reactions for the students and aspirants of Chemistry12th.pptx
Organic Name Reactions  for the students and aspirants of Chemistry12th.pptxOrganic Name Reactions  for the students and aspirants of Chemistry12th.pptx
Organic Name Reactions for the students and aspirants of Chemistry12th.pptx
 
Types of Journalistic Writing Grade 8.pptx
Types of Journalistic Writing Grade 8.pptxTypes of Journalistic Writing Grade 8.pptx
Types of Journalistic Writing Grade 8.pptx
 
KSHARA STURA .pptx---KSHARA KARMA THERAPY (CAUSTIC THERAPY)————IMP.OF KSHARA ...
KSHARA STURA .pptx---KSHARA KARMA THERAPY (CAUSTIC THERAPY)————IMP.OF KSHARA ...KSHARA STURA .pptx---KSHARA KARMA THERAPY (CAUSTIC THERAPY)————IMP.OF KSHARA ...
KSHARA STURA .pptx---KSHARA KARMA THERAPY (CAUSTIC THERAPY)————IMP.OF KSHARA ...
 
18-04-UA_REPORT_MEDIALITERAСY_INDEX-DM_23-1-final-eng.pdf
18-04-UA_REPORT_MEDIALITERAСY_INDEX-DM_23-1-final-eng.pdf18-04-UA_REPORT_MEDIALITERAСY_INDEX-DM_23-1-final-eng.pdf
18-04-UA_REPORT_MEDIALITERAСY_INDEX-DM_23-1-final-eng.pdf
 
Framing an Appropriate Research Question 6b9b26d93da94caf993c038d9efcdedb.pdf
Framing an Appropriate Research Question 6b9b26d93da94caf993c038d9efcdedb.pdfFraming an Appropriate Research Question 6b9b26d93da94caf993c038d9efcdedb.pdf
Framing an Appropriate Research Question 6b9b26d93da94caf993c038d9efcdedb.pdf
 
Painted Grey Ware.pptx, PGW Culture of India
Painted Grey Ware.pptx, PGW Culture of IndiaPainted Grey Ware.pptx, PGW Culture of India
Painted Grey Ware.pptx, PGW Culture of India
 
Meghan Sutherland In Media Res Media Component
Meghan Sutherland In Media Res Media ComponentMeghan Sutherland In Media Res Media Component
Meghan Sutherland In Media Res Media Component
 
Roles & Responsibilities in Pharmacovigilance
Roles & Responsibilities in PharmacovigilanceRoles & Responsibilities in Pharmacovigilance
Roles & Responsibilities in Pharmacovigilance
 
History Class XII Ch. 3 Kinship, Caste and Class (1).pptx
History Class XII Ch. 3 Kinship, Caste and Class (1).pptxHistory Class XII Ch. 3 Kinship, Caste and Class (1).pptx
History Class XII Ch. 3 Kinship, Caste and Class (1).pptx
 
भारत-रोम व्यापार.pptx, Indo-Roman Trade,
भारत-रोम व्यापार.pptx, Indo-Roman Trade,भारत-रोम व्यापार.pptx, Indo-Roman Trade,
भारत-रोम व्यापार.pptx, Indo-Roman Trade,
 
TataKelola dan KamSiber Kecerdasan Buatan v022.pdf
TataKelola dan KamSiber Kecerdasan Buatan v022.pdfTataKelola dan KamSiber Kecerdasan Buatan v022.pdf
TataKelola dan KamSiber Kecerdasan Buatan v022.pdf
 
Proudly South Africa powerpoint Thorisha.pptx
Proudly South Africa powerpoint Thorisha.pptxProudly South Africa powerpoint Thorisha.pptx
Proudly South Africa powerpoint Thorisha.pptx
 
OS-operating systems- ch04 (Threads) ...
OS-operating systems- ch04 (Threads) ...OS-operating systems- ch04 (Threads) ...
OS-operating systems- ch04 (Threads) ...
 
How to Configure Email Server in Odoo 17
How to Configure Email Server in Odoo 17How to Configure Email Server in Odoo 17
How to Configure Email Server in Odoo 17
 

Alan dopamine and norepinephrine

  • 1. Comparison of Dopamine and Norepinephrinein the Treatment of Shock ALLAN PEPE VASQUEZ TEJADA Medico Residente de Cirugía. HVLE
  • 2. El control de la presión tiene dos regulaciones Regulación rápida Barorreceptores de alta presión y de baja presión Regulacion de largo plazo
  • 3. El centro de la presión arterial se encuentra en el bulbo raquídeo rostral ventrolateral y se conecta con la columna intermedio lateral de la medula espinal y con el vago. La noradrenalina, la adrenalina y dopamina son vasopresoresendogenos que tiene diferente forma de acción
  • 5.
  • 6.
  • 7. DOPAMINA La dopamina (3,4-dihidroxifeniletilamina) produce vasodilatación renal Causan estimulación del miocardio Estimulan la frecuencia cardíaca y la vasoconstricción periférica
  • 8. Actualmente la dopamina no está recomendada a dosis bajas Estas acciones determinan un incremento en el consumo de oxígeno miocárdico debido a un aumento en la frecuencia cardíaca y en la vasoconstricción coronaria En pacientes con miocardio agudamente isquémico, la dopamina puede inducir arritmias y precipitar angina.
  • 9. NORADRENALINA Es un agonista potente de los receptores –adrenérgicos El gasto cardíaco persiste sin cambios o está disminuido Aumenta en grado importante el flujo coronario Recomendada la infusión de norepinefrina en choque donde no se logra una estabilidad con la dopamina
  • 10. "La dopamina es el fármaco de elección para el shock" (Vincent 1999).“ se indica para revertir la hipotensión hemodinámicamente significativa debida a infarto miocárdico, traumatismo, sepsis, insuficiencia cardíaca manifiesta, insuficiencia renal, insuficiencia cardíaca congestiva crónica..." (Levy 1992). "La norepinefrina parece ser sumamente útil en el tratamiento del shock causado por disminución inapropiada en la resistencia vascular periférica como el shock séptico y el neurogénico"
  • 11. "La epinefrina se indica principalmente para los estados de gasto cardíaco bajo" (Sladen 1999) y se recomienda como "el tratamiento de primera línea en pacientes con shock anafiláctico" (Breithaupt 2000; Vincent 1999). "La dobutamina es muy eficaz en pacientes con miocardiopatía e insuficiencia cardíaca congestiva" (Sladen 1999).
  • 12. Tres estudios compararon norepinefrina con dopamina (Marik 1994; Martin 1993; Ruokonen 1993): 16 pacientes de 31 murieron en el grupo de norepinefrina en comparación con 19 de 31 en el grupo de dopamina (RR 0,88; 0,57 a 1,36) (ver comparación 02, el resultado 01).
  • 14. Theadministration of fluids, which is the first-line therapeutic strategy, is often insufficient to stabilize the patient’s condition, and adrenergic agents are frequently required to correct hypotension.
  • 15. Dopamineand norepinephrine influence alpha-adrenergic and beta-adrenergic receptors, but to different degrees Dopamine and norepinephrine may have different effects on the kidney, the splanchnic region, and the pituitary axis, but the clinical implications of these differences are still uncertain.
  • 16. Multicentertrial betweenDecember19, 2003, and October 6, 2007, in eight centers in Belgium, Austria, and Spain. 18 years of age or older
  • 17. Thepatientwasconsideredto be in shock if the PAM was less than 70 mm Hg or the PAS was less than 100 mm Hg o there was an elevation in the central venous pressure to >12 mm Hg and if there were signs of tissue hypoperfusion
  • 18. Patientswere excluded if had already received a vasopressoragentfor more than 4 hours during the current episode of shock had a serious arrhythmia had been declaredbrain-dead.
  • 19. The study period lasted a maximum of 28 days The primary end point of the trial was the rate of deathat 28 days
  • 20. A total of 1679 patients were enrolled — 858 in the dopamine group and 821 in the norepinephinegroup. Therewere no significantdifferences between the two groups withregardto most of the baseline characteristics
  • 21.
  • 22.
  • 23. The type of shock that was seen most frequently was septic shock (in 1044 patients ), followed by cardiogenic shock (in 280 patients) and hypovolemicshock (in 263 patients). Hydrocortisone was administered in 344 patients who received dopamine (40.1%) and in 326 patients who received norepinephrine(39.7%)
  • 24. There were no major between-group differences in the total amounts of fluid given, although patients in the dopamine group received more fluids on day 1 Urine output was significantly higher during the first 24 hours in the dopamine group than among those in the norepinephrine group, but this difference eventually disappeared, so that the fluid balance was quite similar between the twogroups.
  • 25. Therewere no significantdifferences in the causes of death between the two groups, although death from refractory shock occurred more frequently in the group of patients treated with dopamine than in the group treated with norepinephrine (P = 0.05)
  • 26. More patients had an arrhythmia, especially atrial fibrillation, in the dopamine group than in the norepinephrinegroup The rate of death at 28 days was significantly higher among patients with cardiogenic shock who were treated with dopamine than among those with cardiogenic shock who were treated with norepinephrine (P = 0.03)
  • 27. The rate of death at 28 days was significantly higher among patients with cardiogenic shock who were treated with dopamine than among those with cardiogenic shock who were treated with norepinephrine (P = 0.03)
  • 28.
  • 29.
  • 31. The rate of death did not differ significantly between the group of patients treated with dopamine and the group treated with norepinephrine Dopamine was associated with more arrhythmic events than was norepinephrine Dopaminewasassociatedwith a significant increase in the rate of death in the predefined subgroup of patients with cardiogenicshock.